Beam Therapeutics Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $307,000 (-96.8% year over year) and diluted EPS of -$1.28. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
-96.8%
|
-134
-19.4%
|
-1.28
-16.4%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-94.2%
|
-123
-20.1%
|
-1.18
-18.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
32
+324.9%
|
-94
+12.9%
|
-0.91
+26.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
114
+279.5%
|
243
+369.0%
|
2.36
+316.6%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
10
-32.0%
|
-113
-16.5%
|
-1.10
+6.0%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
8
-28.1%
|
-102
-12.2%
|
-1.00
+9.9%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
7
+0.8%
|
-108
-9.8%
|
-1.23
-1.7%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
30
-90.5%
|
-90
-163.3%
|
-1.09
-161.8%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BEAM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1745999
- Former names
- Beam Therapeutics Inc. (until Nov 3, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.